Severe Bradycardia and Asystole Following Regadenoson in Pharmacological Myocardial Perfusion Imaging

Regadenoson for myocardial perfusion imaging: Is it safe?

Regadenoson is currently the most widely used pharmacologic stress agent for myocardial perfusion imaging (MPI) with millions of doses administered annually in the US. In November 2013, the US Food and Drug Administration (FDA) issued a Drug Safety Communication warning health care professionals of the rare but serious risk of heart attack and death with use of either regadenoson or adenosine. ...

Serious complications associated with regadenoson administration for myocardial perfusion imaging

The Editorial by Hage and Iskandrian regarding ‘‘Serious complications associated with regadenoson administration for myocardial perfusion imaging: A commentary’’ (September/October 2014 issue) includes a table as a guide for serious complications associated with regadenoson administration. In the table, the authors reported whether or not each listed event occurs with exercise and/or adenosine...

Regadenoson Cardiac Stress Myocardial Perfusion Scintigraphy

Evaluation of some blood parameters alteration following low-dose radiation induced by Myocardial Perfusion Imaging

Purpose: With  increasing the usage  of  myocardial  perfusion  imaging  (MPI)  for  the diagnosis  of  ischemic  heart  disease,  we  aimed  to  evaluate  the  side  effects  of  low-dose  radiation  induced  by  this  technique  on blood elements, especially proteins and liver function factors.Materials and  Methods:  40  eligible  patients  (Mean  age:  54.6...

Performance and safety profile of regadenoson myocardial perfusion imaging: first experience in Greece.

OBJECTIVE MPI can provide valuable information in the investigation of patients with known or suspected coronary artery disease. The stress component of the studies can be conducted with regadenoson, which was approved for clinical use in Greece in 2016. We investigated the performance and safety profile of regadenoson MPI based on our 7 months institutional experience. PATIENTS AND METHODS W...